Summary:
In adults with obesity or overweight without type 2 diabetes, tirzepatide treatment significantly improved β-cell function and insulin sensitivity compared to baseline, though it was associated with some gastrointestinal side effects, such as nausea and diarrhea.
| PICO | Description |
|---|---|
| Population | Adults with obesity or overweight without type 2 diabetes, including individuals with prediabetes or normoglycemia. |
| Intervention | Treatment with tirzepatide, a dual GLP-1/GIP receptor agonist, administered subcutaneously once weekly. |
| Comparison | Baseline measures of β-cell function and insulin sensitivity, with weight reduction considered as a covariate. |
| Outcome | Tirzepatide treatment resulted in significant improvements in β-cell function and insulin sensitivity compared to baseline. These improvements were partly independent of weight loss. However, gastrointestinal side effects, including nausea and diarrhea, were reported as common adverse events. |
Source: Andrea Mari, et al. “Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.” Read article here.
